Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Auris O Huen Image

      Auris O Huen, MD, PharmD

      Department of Dermatology, Division of Internal Medicine

      in the News

      Close-up of unidentified white woman scratching her back beneath a sports bra

      Mycosis fungoides: 11 things to know about this rare lymphoma subtype

      Close-up look at ultraviolet light device

      Can UV light really be used as a cancer treatment?

      Present Title & Affiliation

      Primary Appointment

      Advanced Practice Provider Manager, Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Chief, Section of Cutaneous Lymphoma, Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Associate Professor, Dermatology, Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Chief, Section of Cutaneous Lymphoma, Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Associate Professor, Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Education & Training

      Degree-Granting Education

      2011The University of Texas Medical Branch, Galveston, Texas, US, Medicine, MD
      1999The University of Texas at Austin, Austin, Texas, US, Doctor of Pharmacy, PHARMD

      Postgraduate Training

      2012-2015Residency in Dermatology, Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
      2011-2012Internship in Medicine, Baylor College of Medicine, Houston, Texas
      2000-2001Residency in Oncology Pharmacy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
      2000-2000Residency in Clinical Pharmacy Practice, Chief Resident, University of California, San Francisco, California
      1999-2000Residency in Clinical Pharmacy Practice, University of California, San Francisco, California

      Licenses & Certifications

      2015American Board of Dermatology: Board Certified Dermatologist
      2015Texas Medical Board
      2002Board of Pharmacy Specialties: Board Certified Oncology Pharmacist (BCOP)

      Experience & Service

      Faculty Academic Appointments

      Assistant Professor, Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2015 - 2021

      Clinical Instructor, The University of Texas at Austin College of Pharmacy, Austin, TX, 2006 - 2007

      Administrative Appointments/Responsibilities

      Advanced Practice Provider Manager, Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present

      Advanced Practice Provider Supervisor, Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024

      Other Professional Positions

      Staff Pharmacist (Per Diem), Walgreens Pharmacy, Houston, TX, 2008 - 2010

      Hematology Oncology Clinical Pharmacist Specialist, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 2001 - 2007

      Pharmacy Technician - Retail Pharmacy, Albertson's Pharmacy, San Antonio, TX, 1998 - 1999

      Texas Society of Health-System Pharmacists Summer Pharmacy Intern, Owen Healthcare, Houston, TX, 1997 - 1997

      Pharmacy Technician - Hospital Pharmacy, Austin Diagnostic Medical Center, Austin, TX, 1997 - 1997

      Extramural Institutional Committee Activities

      Member, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2023 - 2026

      Member, Pressure Injury Coding and Documentation Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2024

      Chair, T-Cell Lymphoma Tumor Board, The University of Texas MD Anderson Cancer Center, 2018 - Present

      Member, Skin Integrity Task Force, The University of Texas MD Anderson Cancer Center, 2017 - 2024

      Member, Institutional Faculty Senate, The University of Texas MD Anderson Cancer Center, 2016 - 2022

      Editorial Activities

      Editorial Board Member, Journal of the American Academy of Dermatology Case Reports, 2025 - Present

      Honors & Awards

      2021 - 2024Excellence in Patient Care, Division of Internal Medicine
      2011 - 2024American Medical Women's Association Glasgow - Rubin Citation for Academic Achievement, University of Texas Medical Branch, Galveston, TX
      2011 - 2024Johanna Blumel Memorial Scholarship for Academic Excellence, University of Texas Medical Branch
      2010 - 2024Alpha Omega Alpha Honor Medical Society - Junior Inductee, Alpha Omega Alpha Honor Medical Society
      2010Who's Who Among Students in American Universities and Colleges
      2007 - 2011Dr. Walter J. Hildebrand Academic Scholarship, University of Texas Medical Branch
      1996 - 2024Rho Chi Pharmaceutical Honor Society-Elected Member

      Professional Memberships

      United States Cutaneous Lymphoma Consortium

      2023 - Present

      International Society of Cutaneous Lymphoma

      2020 - Present

      Houston Dermatological Society

      2015 - Present

      American Academy of Dermatology

      2012 - Present

      Alpha Omega Alpha Honor Medical Society Texas Alpha Chapter

      2010 - Present

      Dermatology Interest Group University of Texas Medical Branch

      2010 - 2011

      Selected Presentations & Talks

      Local Presentations

      1. 2023. Cutaneous T-cell Lymphoma. CME Lecture, Grand Rounds Conference. Invited. University of Texas Medical Branch. Galveston, TX, US.
      2. 2022. Cutaneous T-cell Lymphoma Past, Present, Future. Conference. Houston Dermatological Society. Houston, TX, US.
      3. 2022. Cutaneous T-cell Lymphoma. Invited. MD Anderson Cancer Center. Houston, TX, US.
      4. 2019. Cutaneous Lymphoma. Invited. Radiation Oncology Resident Didactic Lecture. Houston, TX, US.
      5. 2019. Next Generation Sequencing for T-cell Lymphoma. Invited. MD Anderson MTEC Committee Meeting. Houston, TX, US.
      6. 2019. Mycosis fungoides. Invited. Division of Internal Medicine Resident Noon Conference. Houston, TX, US.
      7. 2018. Mycosis Fungoides: Clinical and Pathology Correlation. Invited. Division of Pathology and Laboratory Medicine’s Grand Rounds. Houston, TX, US.
      8. 2018. Quality of Life in Cutaneous T-Cell Lymphoma Patients Treated with Anti-CCR4 Monoclonal Antibody Mogamulizumab vs. Vorinostat: Results from MAVORIC. Poster. Society of Hematologic Oncology. Houston, Texas, US.
      9. 2017. Mycosis Fungoides, Clinical and Research Conference. Invited. The University of Texas M.D. Anderson Cancer Center. Houston, TX, US.
      10. 2017. Managing Skin Toxicities in the Cancer Patient. Invited. Houston Chapter of the Oncology Nursing Society. Houston, TX, US.
      11. 2017. Mycosis Fungoides: New Treatment Options:. Invited. Houston Dermatological Society. Houston, TX, US.
      12. 2016. Mycosis Fungoides: New Treatment Strategies, Internal Medicine & Cancer Survivorship Grand Rounds,. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.

      Regional Presentations

      1. 2023. Molecular Testing for Cutaneous Lymphomas. Conference. Texas Dermatological Society Conference. San Antonio, Texas, US.
      2. 2021. Cutaneous T-cell Lymphoma. CME Lecture, Virtual Grand Rounds. Invited. Baylor, Scott and White, US.
      3. 2019. Mycosis Fungoides and Updates on Treatment. Conference. Texas Dermatological Society. Houston, TX, US.
      4. 2018. Hidradenitis Supprativa Associated with Sorafenib Initiation. Poster. Texas Dermatological Society Annual Fall Meeting. Galveston, Texas, US.
      5. 2018. A Case of Mucous Membrane Pemphigoid Associated with Pembrolizumab. Poster. Texas Dermatological Society Annual Fall Meeting. Galveston, Texas, US.
      6. 2018. A case of poziotinib-induced acneiform-like eruption cleared with minocycline. Poster. Texas Dermatological Society Annual Fall Meeting. Galveston, Texas, US.
      7. 2017. Basals Behaving Badly: A Case Highlighting Current and Emerging Targeted Therapies. Poster. Texas Dermatological Society Annual Fall Meeting 2017. Bastrop, TX, US.
      8. 2016. EBV-positive lymphoproliferative disorder presenting as a hypersensitivity reaction. Poster. Texas Dermatological Society Annual Meeting. Houston, Texas.
      9. 2014. Gorlin Phenotype in Chromosome 9 Microdeletion Syndrome. The 115th Annual Meeting of the Philadelphia Dermatological Society. Panelist. The Philadelphia Dermatological Society. Philadelphia, PA, US.
      10. 2014. Chromoblastomycosis, Duhring Conference. Panelist. University of Pennsylvania. Philadelphia, PA, US.
      11. 2014. Cellular Grafting in Vitiligo. Duhring Conference. Panelist. University of Pennsylvania. Philadelphia, PA, US.

      National Presentations

      1. 2026. Jak Inhibitors: Friend of Foe. Conference. American Academy of Dermatology Annual Meeting. Denver, Colorado.
      2. 2026. Impact of Large Cell Transformation on CTCL Management: Considerations for Dermatologist. Conference. American Academy of Dermatology Annual Meeting. Denver, Colorado, US.
      3. 2026. Jak Inhibitors: Friend of Foe in CTCL. Conference. United States Cutaneous Lymphoma Consortium Annual Workshop and Conference. Denver, Colorado.
      4. 2025. Advanced Stage Cutaneous Lymphoma in the Pediatric Patient. Panelist. United States Cutaneous Lymphoma Consortium Tumor Board.
      5. 2025. Jak Inhibitors: Friend or Foe in CTCL. Conference. American Academy of Dermatology Annual Meeting. Orlando, Florida, US.
      6. 2025. Treatment of Adult T-cell Leukemia Lymphoma with Imiquimod. Conference. United States Cutaneous Lymphoma Consortium Annual Workshop and Conference. Orlando, Florida.
      7. 2022. Prognostic Significance of Cutaneous Angioimmunoblastic T-Cell Lymphoma: Correlation of Clinical, Histologic and Immunophenotypic Features with Response. Poster. American Society of Hematology Annual Meeting. New Orleans, Louisiana, US.
      8. 2021. Dupilumab associated cutaneous T-cell lymphoma. Poster. United States Cutaneous Lymphoma Consortium Virtual Conference, US.
      9. 2021. CD8 Aggressive Epidermotropic T-cell Lymphoma, Case Presentation and Clinical Pathological Correlation. Invited. VMX Virtual Conference, US.
      10. 2021. Cutaneous T-cell Lymphoma: Updates on Management. Invited. University of Vermont and Vermont Dermatological Society. Burlington, VT, US.
      11. 2020. Cutaneous Toxicities of Cancer Treatment. Invited. MD Anderson Cancer Network Broadcast. Houston, TX, US.
      12. 2019. A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). Poster. American Society of Hematology Annual Meeting. Orlando, FL, US.
      13. 2019. Mycosis Fungoides: Updates on Treatment and Diagnosis. Invited. American Academy of Dermatology Summer Annual Meeting. New York, NY, US.
      14. 2019. Cutaneous T-cell Lymphoma. Invited. Oklahoma State Dermatological Society. Tulsa, OK, US.
      15. 2018. Multifocal Primary Cutaneous Mucinous Adenocarcinoma. Poster. American Society of Dermatopathology Annual Meeting. Chicago, IL, US.
      16. 2018. Tenalisib, a dual P13K ä/ã inhibitor; Safety and efficacy results from an on-going Phase I/lb study in patients with relapsed/refractory T-Cell Lymphoma. Poster. American Society of Clinical Oncology Annual Meeting. Chicago, IL, US.
      17. 2017. Mycosis Fungoides: New Treatment Option. Visiting. Jupiter Medical Center CME Conference. Jupiter, Florida, US.
      18. 2017. Gabapentin and Pregabalin for the Treatment Cutaneous Lymphoma Associated Pruritus. Oral Presentation,. Conference. Medical Dermatology Society Annual Meeting. Orlando, FL, US.
      19. 2016. Mycosis Fungoides: Challenging cases and treatment options. Invited. Department of Dermatology Resident Lecture Series. Philadelphia, PA, US.
      20. 2015. Mutation Associated with Leukemia Cutis, NPMI Associated with leukemia cutis, Medical Dermatology Society Annual Meeting, Oral Presentation. Invited. Medical Dermatology Society. San Francisco, CA, US.
      21. 2015. NPMI Mutation Associated with leukemia cutis. Oral Presentation. Conference. Medical Dermatology Society Annual Meeting. San Francisco, CA, US.
      22. 2010. Anti-tumor effects of sapacitabine in cutaneous T-cell lymphoma (CTCL) cells, Society for Investigative Dermatology Annual Meeting. Poster. Society for Investigative Dermatology Annual Meeting. Cleveland, Ohio, US.
      23. 2008. Principles of Chemotherapy for the Non-Oncologist, institutional Grand Rounds. Invited. Waukesha Memorial Hospital. Waukesha, WI, US.
      24. 2003. Ontak: Novel treatment of T-cell Lymphoma, Damashek Cancer Symposium. Invited. Leukemia and Lymphoma Society. Wichita, KS, US.
      25. 2001. Myelosuppression and serotonin syndrome associated with linezoilid and selective serotonin re-uptake inhibitors (SSRIs), Annual Meeting of the Infectious Diseases Society of America. Poster. Infectious Diseases Society of America. San Francisco, CA, US.
      26. 1999. Comparison of In Vitro Activity of Voriconazole, SCH-56592, and Fluconsole against Candida albicans by Time-Kill Methodology. Poster. The 1999 International Congress on Clinical Pharmacy and American College of Clinical Pharmacy Spring Research Forum, American College of Clinical Pharmacy. Lenexa, Kansas, US.

      International Presentations

      1. 2024. Response to Topical Ruxolitinib in Patient with Folliculotropic Mycosis Fungoides. Poster. European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Meeting. Lausanne, CH.
      2. 2023. Retreatment with Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis. Poster. World Congress of Dermatology. Singapore, SG.
      3. 2018. Updated Combined Analysis of Two Phase II Studies of Brentuximab Vedotin in Patients with Mycosis Fungoides and Sezary Syndrome, Oral Presentation. Conference. European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Meeting. St. Galen, CH.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - Present
      Title:Sterling Foundation Research Grant
      Funding Source:Private Donor
      Role:PI
      Title:Robert C. Ammann III Cutaneous Lymphoma Mycosis Fungoides Research Fund
      Funding Source:Private Donor
      Role:Steward

      Selected Publications

      Peer-Reviewed Articles

      1. Park JB, Geller S, Liao V, Purnak S, Huen A, Iyer SP, Pierog O, Leibovit-Reiben Z, Mangold AR, Scribner J, Talluru SM, Stockard AL, Vroman J, Weiner J, Allen PB, Rozati S. Clinicopathologic Features and Long-Term Outcomes of Adult Hypopigmented Mycosis Fungoides 162(8):780-786, 2026. e-Pub 2026. PMID: 42307910.
      2. Lohray R, Purnak S, Huen A, Duvic M, Dai J. Long-term outcomes in juvenile-onset mycosis fungoides. J Am Acad Dermatol 95(2):409-415, 2026. e-Pub 2026. PMID: 41780598.
      3. Meng C, Huen A, McCall D, Aung PP, Nagarajan P, Nardi V, Torres-Cabala CA. Pediatric Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma With Unusually Long Clinical Course. J Cutan Pathol 53(4):340-346, 2026. e-Pub 2026. PMID: 41400112.
      4. Allen PB, Goyal S, Iyer S, Talluru S, Huen A, Greenwell B, Scribner J, Paulino D, Speegle S, Baird K, Beaven A, Switchenko JM, Rangarajan S, Mehta A, O'Leary C, Case K, Adams B, Ayers A, Bhatti S, Krishnasamy S, Porcu P, Sethi T, Foss F, Lechowicz MJ, Rozati S. Racial differences in mycosis fungoides and Sézary syndrome: A multicenter cohort study. J Am Acad Dermatol 94(2):509-516, 2026. e-Pub 2026. PMID: 41033490.
      5. Lohray R, Purnak S, Arkatkar S, Duvic M, Prieto V, Torres-Cabala C, Huen A. Tumor flare reaction with brentuximab-vedotin in mycosis fungoides. JAAD Case Reports 6(70):39-41, 2026. e-Pub 2026. PMID: 41798142.
      6. Fason, C, Tyring, SK, Huen, A. Primary cutaneous anaplastic large cell lymphoma: Clinical response with low dose brentuximab vedotin on a patient receiving hemodialysis. JAAD Case Reports 62:116-118, 2025. e-Pub 2025. PMID: 40740736.
      7. Goyal, A, O'Leary, D, Dabaja, BS, Weng, WK, Zain, J, Cutler, C, Guitart, J, Kim, YH, Geskin, L, Hoppe, RT, Wilson, LD, Beaven, A, Horwitz, SM, Allen, PB, Barta, S, Bohjanen, K, Brammer, JE, Carter, JB, Comfere, N, Desimone, JA, Dusenbery, K, Duvic, M, Huen, A, Jagadeesh, D, Kelsey, CR, Khodadoust, MS, Lechowicz, MJ, Mehta-Shah, N, Moskowitz, AJ, Olsen, EA, Poh, C, Pro, B, Querfeld, C, Sauter, C, Sokol, L, Sokumbi, O, Wilcox, RA, Zic, J, Gru, A, Hamadani, M, Foss, FM. ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome. Journal of the American Academy of Dermatology 93(2):387-397, 2025. e-Pub 2025. PMID: 40199382.
      8. Fenner, BE, Burningham, KM, Thomas, JL, Kelly, B, Huen, A, Tyring, SK. The Great Mimicker. American Journal of Medicine Open 13, 2025. e-Pub 2025. PMID: 40201427.
      9. Wu, SY, Damron, EP, Xu, J, Fang, PQ, Dai, J, Nair, R, Malpica Castillo, LE, Fayad, LE, Torres Cabala, CA, Medeiros, LJ, Vega Vazquez, F, Miranda, R, Duvic, M, Pinnix, CC, Dabaja, BS, Iyer, S, Huen, A, Gunther, J. Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. International Journal of Dermatology 64(2):385-389, 2025. e-Pub 2025. PMID: 38955474.
      10. Iyer, SP, Sica, RA, Ho, J, Prica, A, Zain, J, Foss, FM, Hu, B, Beitinjaneh, AM, Weng, WK, Kim, YH, Khodadoust, MS, Huen, A, Williams, LM, Ma, A, Huang, E, Ganpule, A, Nagar, SD, Sripakdeevong, P, Cullingford, EL, Karnik, S, Dequeant, ML, Patel, JN, He, XS, Li, Z, He, QA, Mendonez, JH, Keegan, A, Horwitz, SM. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM). The lancet oncology 26(1):110-122, 2025. e-Pub 2025. PMID: 39617017.
      11. Fang, PQ, Noticewala, SS, Wu, SY, Gunther, J, Ludmir, EB, Medeiros, LJ, Strati, P, Nair, R, Nze, CC, Nastoupil, L, Ahmed, S, Castillo, LM, Fayad, LE, Westin, J, Neelapu, SS, Flowers, CR, Huen, A, Iyer, SP, Dabaja, BS, Pinnix, CC. Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type. Advances in Radiation Oncology 9(12), 2024. e-Pub 2024. PMID: 39553398.
      12. Purnak, S, Hosing, C, Dabaja, BS, Bassett Jr, R, Huen, A, Duvic, M. On the Way to Curing Advanced-Stage Mycosis Fungoides/Sézary Syndrome. Clinical Lymphoma, Myeloma and Leukemia 24(12):827-836, 2024. e-Pub 2024. PMID: 39107202.
      13. Goyal, A, O'Leary, D, Dabaja, BS, Weng, WK, Zain, J, Cutler, C, Guitart, J, Kim, YH, Geskin, L, Hoppe, RT, Wilson, LD, Beaven, A, Horwitz, SM, Allen, PB, Barta, S, Bohjanen, K, Brammer, JE, Carter, JB, Comfere, N, Desimone, JA, Dusenbery, K, Duvic, M, Huen, A, Jagadeesh, D, Kelsey, CR, Khodadoust, MS, Lechowicz, MJ, Mehta-Shah, N, Moskowitz, AJ, Olsen, EA, Poh, C, Pro, B, Querfeld, C, Sauter, C, Sokol, L, Sokumbi, O, Wilcox, RA, Zic, J, Hamadani, M, Foss, FM. ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome. Transplantation and Cellular Therapy 30(11):1047-1060, 2024. e-Pub 2024. PMID: 39222792.
      14. Marques-Piubelli, ML, Navarrete, J, Ledesma, D, Hudgens, CW, Segura Lazcano, R, Alani, A, Huen, A, Duvic, M, Nagarajan, P, Aung, PP, Wistuba, II, Curry, JL, Miranda, RN, Torres Cabala, CA. Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides. Cells 13(5), 2024. e-Pub 2024. PMID: 38474383.
      15. Iyer, SP, Huen, A, Ai, W, Jagadeesh, D, Lechowicz, MJ, Okada, C, Feldman, T, Ghione, P, Alderuccio, JP, Champion, R, Kim, SH, Mohrbacher, AF, Routhu, KV, Barde, PJ, Nair, A, Haverkos, B. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma. Haematologica 109(1):209-219, 2024. e-Pub 2024. PMID: 37439343.
      16. Lauck K, Ahmad AS, Nguyen QD, Yang Z, Kundu S, Huen AO. Management strategies and survival in cutaneous B-cell lymphoma: A population based study. JAAD Int 13:28-29, 2023. e-Pub 2023. PMID: 37592974.
      17. Nguyen CN, Iyer SP, Duvic M, Barde PJ, Nair A, Routhu KV, Huen AO. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome. Invest New Drugs 41(2):350-355, 2023. e-Pub 2023. PMID: 37004644.
      18. Wu SY, Fang PQ, Wang EB, Ahmed S, Duvic M, Jain P, Castillo LEM, Nair R, Steiner RE, Strati P, Huen AO, Iyer SP, Pinnix CC, Dabaja BS, Gunther JR. Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma. Adv Radiat Oncol 8(6):101279, 2023. e-Pub 2023. PMID: 37448588.
      19. Bur D, Patel AB, Nelson K, Huen A, Pacha O, Phillips R, Heberton M. A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes. J Am Acad Dermatol 87(6):1394-1395, 2022. e-Pub 2022. PMID: 35940366.
      20. Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. JAMA Dermatol 158(9):1031-1039, 2022. e-Pub 2022. PMID: 35857290.
      21. Bartley BR, Huen A, Rady PL, Tyring SK, Nagarajan P, Aung PP, Curry JL, Ivan D, Torres-Cabala CA, Prieto VG, Cho WC. Eosinophilic homogeneous intracytoplasmic inclusion bodies: Unique viral cytopathic changes associated with epidermodysplasia verruciformis and human papillomavirus type 49. J Cutan Pathol 49(7):658-662, 2022. e-Pub 2022. PMID: 35262953.
      22. Patel AB, Farooq S, Welborn M, Amaria RN, Chon SY, Diab A, Glitza Oliva IC, Huen AO, Li SQ, Nelson KC, Pacha O, Patel SP, Rapini RP, Tawbi HA, Wong MK, McQuade J, Davies MA, Haydu LE. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer 128(5):975-983, 2022. e-Pub 2022. PMID: 34724197.
      23. Lo JJ, Heberton MM, Pacha O, Huen AO, Patel AB. Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single institution study of 17 consecutively treated patients. Support Care Cancer 30(2):989-994, 2022. e-Pub 2022. PMID: 34519869.
      24. Nguyen CN, Iyer SP, Miranda RN, Torres-Cabala CA, Curry JL, Fang P, Thomas VD, Huen AO. Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse. JAAD Case Rep, 2021. e-Pub 2021. PMID: 34692965.
      25. Collins K, Gu J, Aung PP, Nagarajan P, Curry JL, Huen A, Ivan D, Prieto VG, Tetzlaff MT, Duvic M, Miranda RN, Vega F, Torres-Cabala CA. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?. Virchows Arch 479(2):377-383, 2021. e-Pub 2021. PMID: 33604757.
      26. Lyapichev KA, Bah I, Huen A, Duvic M, Routbort MJ, Wang W, Jorgensen JL, Medeiros LJ, Vega F, Craig FE, Wang SA. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells. Cytometry B Clin Cytom 100(2):183-191, 2021. e-Pub 2021. PMID: 32667737.
      27. Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L, Beylot-Barry M, Floden L, Bagot M, Tsianakas A, Moskowitz A, Huen A, Dreno B, Dalle S, Caballero D, Leoni M, Dale S, Herr F, Duvic M. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clin Lymphoma Myeloma Leuk 21(2):97-105, 2021. e-Pub 2021. PMID: 33158772.
      28. Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SP. Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers (Basel) 12(8), 2020. e-Pub 2020. PMID: 32824175.
      29. Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer 133:120-130, 2020. e-Pub 2020. PMID: 32502876.
      30. Jenkinson HA, Aung PP, Huen A. Mycosis fungoides manifesting as a morbilliform eruption mimicking a viral exanthem. Cutis 105(6):E27-E29, 2020. e-Pub 2020. PMID: 32717002.
      31. Limmer AL, Park KE, Patel AB, Huen AO. Unusual presentation of Kaposi sarcoma in an HIV-negative woman. Dermatol Online J 26(4), 2020. e-Pub 2020. PMID: 32621687.
      32. Tran J, Huen A, Duvic M. Renal Cell Carcinoma Associated with Mycosis Fungoides: A Paraneoplastic Syndrome. Case Rep Nephrol 2020:8897183, 2020. e-Pub 2020. PMID: 33178469.
      33. Messer A, Brown AE, Pacha O, Boddu P, Geppner A, Kadia TM, Huen AO. Successful treatment of cutaneous adult T-cell leukemia/lymphoma with imiquimod. JAAD Case Rep 5(11):979-981, 2019. e-Pub 2019. PMID: 31709290.
      34. Emge DA, Bassett RL, Duvic M, Huen AO. Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients. Arch Dermatol Res, 2019. e-Pub 2019. PMID: 31776647.
      35. Ibarra BS, Huen A, Nagarajan P, Torres-Cabala CA, Prieto VG, Aung PP. From mycosis fungoides to herpetic folliculitis: The significance of deeper H&E tissue sections in dermatopathology. J Cutan Pathol 46(8):624-626, 2019. e-Pub 2019. PMID: 30883857.
      36. Morse DC, Chockalingam R, Pye A, Huen A. Hidradenitis suppurativa associated with sorafenib initiation. Dermatol Online J 25(6), 2019. e-Pub 2019. PMID: 31329396.
      37. Jensen GL, Dabaja BS, Pinnix CC, Gunther JR, Huen A, Duvic M, Oki Y, Fanale M, Hosing C, Milgrom SA. Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. Case Rep Oncol 11(3):721-728, 2018. e-Pub 2018. PMID: 30519174.
      38. Aria AB, Chen L, Huen AO. A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report. SAGE Open Med Case Rep 6:2050313X18795075, 2018. e-Pub 2018. PMID: 30214807.
      39. Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, Duvic M. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol 153(12):1302-1306, 2017. e-Pub 2017. PMID: 28980004.
      40. Wieser I, Huen A, Bush AE, Dabaja BS, Duvic M. Periorbital Involvement in Early Stage Mycosis Fungoides. Acta Derm Venereol 97(8):976-978, 2017. e-Pub 2017. PMID: 28421231.
      41. Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, Aung PP, Torres-Cabala CA, Mays SR, Prieto VG, Curry JL. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. Am J Dermatopathol 39(2):121-129, 2017. e-Pub 2017. PMID: 28134729.
      42. Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, Nagarajan P, Huen A, Aung PP, Ivan D, Drucker CR, Prieto VG, Rapini RP, Patel A, Curry JL. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol 43(8):688-96, 2016. e-Pub 2016. PMID: 27086658.
      43. Tracey EH, Huen AO, Sreih AG, Evans T, Kobrin S, Rubin AI, Rosenbach M. Paraneoplastic microscopic polyangiitis presenting after thymectomy. JAAD Case Rep 2(2):153-5, 2016. e-Pub 2016. PMID: 27222874.
      44. Huen A, Fett N. An enormous tumor in a patient with clinically amyopathic dermatomyositis: answer. Am J Dermatopathol 37(11):870, 2015. e-Pub 2015. PMID: 26485242.
      45. Luskin MR, Huen AO, Brooks SA, Stewart C, Watt CD, Morrissette JJ, Lieberman DB, Bagg A, Rosenbach M, Perl AE. NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features. Haematologica 100(10):e412-4, 2015. e-Pub 2015. PMID: 26113416.
      46. Dai J, Huen AO, Kestenbaum LA, Sarezky MD, Coughlin CC, Yan AC. Achromobacter xylosoxidans Bacteremia and Cellulitis: A Report of a Case. Pediatr Dermatol 32(4):e186-7, 2015. e-Pub 2015. PMID: 25973735.
      47. Wynes J, Wanat KA, Huen A, Mlodzienski AJ, Rubin AI. Pigmented Onychomatricoma: A Rare Pigmented Nail Unit Tumor Presenting as Longitudinal Melanonychia That Has Potential for Misdiagnosis as Melanoma. J Foot Ankle Surg 54(4):723-5, 2015. e-Pub 2015. PMID: 25060607.
      48. Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series. Cancer 119(4):825-31, 2013. e-Pub 2013. PMID: 22952039.
      49. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med 123(10):935-41, 2010. e-Pub 2010. PMID: 20920696.
      50. Chaves J, Huen A, Bueso-Ramos C, Safdar A, Vadhan-Raj S. Aerosolized ribavirin-induced reversible hepatotoxicity in a hematopoietic stem cell transplant recipient with Hodgkin lymphoma. Clin Infect Dis 42(8):e72-5, 2006. e-Pub 2006. PMID: 16575720.
      51. Hachem RY, Hicks K, Huen A, Raad I. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis 37(1):e8-11, 2003. e-Pub 2003. PMID: 12830431.

      Review Articles

      1. Akkad N, Huen A, Iyer SP. Targeting cutaneous T-cell lymphoma in non-Hodgkin lymphoma: what's new for investigational agents?. Expert Opin Investig Drugs 21:1-14, 2026. e-Pub 2026. PMID: 41988788.
      2. Seervai RNH, Friske SK, Chu EY, Phillips R, Nelson KC, Huen A, Cho WC, Aung PP, Torres-Cabala CA, Prieto VG, Curry JL. The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy. J Cutan Pathol 50(1):72-95, 2023. e-Pub 2023. PMID: 36069496.
      3. Musiek ACM, Rieger KE, Bagot M, Choi JN, Fisher DC, Guitart J, Haun PL, Horwitz SM, Huen AO, Kwong BY, Lacouture ME, Noor SJ, Rook AH, Seminario-Vidal L, Vermeer MH, Kim YH. Dermatologic events associated with the anti-CCR4 antibody mogamulizumab: characterization and management. Dermatol Ther (Heidelb) 12(1):29-40, 2022. e-Pub 2022. PMID: 34816383.
      4. Torres-Cabala CA, Huen A, Iyer SP, Miranda RN. Gamma/Delta Phenotype in Primary Cutaneous T-cell Lymphomas and Lymphoid Proliferations: Challenges for Diagnosis and Classification. Surg Pathol Clin 14(2):177-194, 2021. e-Pub 2021. PMID: 34023099.
      5. Huen AO, Rook AH. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr Opin Oncol 26(2):237-44, 2014. e-Pub 2014. PMID: 24441505.

      Editorials

      1. Hagemeister F, Huen. The status of allopurinol in the management of tumor lysis syndrome: a clinical review. Cancer Journal 11(1):S1-10, 2005.

      Abstracts

      1. Huen AO, Zanot A, Tran J, Duvic M. Retreatment with Brentuximab Vedotin in Mycosis Fungoides and Lymphomatoid Papulosis, 2023. e-Pub 2023.
      2. Zinzani PL, Ortiz-Romero P, Lima M, Huen AO. Health-related quality if life effect of mogamulizumab by patient blood involvement patient blood involvement. Eur J Cancer:1:S65-S66, 2021. e-Pub 2021. PMID: 34649667.
      3. Iyer S, Rao V, Burns E, Ashu A, Pullokaran L, Vo A, Claussen C, Obi C, Miranda R, Dabaja B, Nieto Y, Hosing C, Lee H, Steiner R, Nair R, Samaniego S, Nastoupil L, Parmar S, Westin J, Fowler N, Ahmed S, Neelapu S, Duvic M, Huen A. A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). American Society of Hematology Annual Meeting, Orlando, FL, 2019. e-Pub 2019.
      4. Messer A, Huen AO, Cataldo V, Curry J, Nagarajan P. Multifocal Primary Cutaneous Mucinous Adenocarcinoma. American Society of Dermatopathology Annual Meeting, November 2018, Chicago, IL, 2018. e-Pub 2018.
      5. Morse D, Chockalingam R, Pye A, Huen A. Hidradenitis Supprativa Associated with Sorafenib Initiation. Texas Dermatological Society Annual Fall Meeting, Galveston, TX, 2018. e-Pub 2018.
      6. Morse D, Muhai D, Torres-Caballa C, Jahan-Tigh R, Huen A. A Case of Mucous Membrane Pemphigoid Associated with Pembrolizumab. Texas Dermatological Society Annual Fall Meeting. September 2018, Galveston, TX, 2018. e-Pub 2018.
      7. Huen AO, Rahbar Z, Talpur R, Li S, Hong EE, Tetzlaff M, Duvic M, Kim YH. Updated Combined Analysis of Two Phase II Studies of Brentuximab Vedotin in Patients with Mycosis Fungoides and Sezary Syndrome. EORTC St. Galen, Switzerland, 2018. e-Pub 2018.
      8. Duke T, Walker K, Huen A. A case of poziotinib-induced acneiform-like eruption cleared with minocycline. Texas Dermatological Society Annual Fall Meeting, Galveston, TX, 2018. e-Pub 2018.
      9. Huen A, Porcu P, Hudgens S, Quaglino P, Cowan R, Floden L, Tsianakas A, Leoni M, Dale S, Duvic M. Quality of Life in Cutaneous T-Cell Lymphoma Patients Treated with Anti-CCR4 Monoclonal Antibody Mogamulizumab vs. Vorinostat: Results from MAVORIC, 2018. e-Pub 2018.
      10. Huen AO, Oki Y, Haverkos B, Zain J, Lechowicz MJ, Devata S Korman N, Ramachandren R Pinter-Brown L, Barde P, Nair A. Tenalisib, a dual P13K δ/γ inhibitor; Safety and efficacy results from an on-going Phase I/lb study in patients with relapsed/refractory T-Cell Lymphoma, 2018. e-Pub 2018.
      11. Messer A, Huen AO. Basals Behaving Badly: A Case Highlighting Current and Emerging Targeted Therapies, 2017. e-Pub 2017.
      12. Chin AV, Duvic MA, Garg, N, Bassett R, Huen AO. Gabapentin and pregabalin for the treatment of cutaneous lymphoma associated pruritus, 2017. e-Pub 2017.
      13. Huen A, Zain J, Querfeld C, Haverkos B, Barole P, Kavandar M, Duvic M, Penmetsa K, Oki Y. Evaluation of RP6530, a Novel dual PI3K δ/γ inhibitor in patients with relaxed/refractory T-Cell Lymphoma, 2017. e-Pub 2017.
      14. Oki Y, Huen AO, Barde P, Penmetsa K, Ashu AJ, Wilson C, Pullokaran L, Viswanadha S, Duvic M. A dose escalation study of RP6530, a novel dual PI3K δ/γ inhibitor, in patients with relapsed/refractory t-cell lymphoma, 2016. e-Pub 2016.
      15. Pickett MM, Sapority RC, Nagarajan P, Huen AO. EBV-positive lymphoproliferative disorder presenting as a hypersensitivity reaction, 2016. e-Pub 2016.
      16. Huen AO, Luskin MR, Steart C, Bagg A, Rosenbach M, Perl A. NPM1 Mutation Associated with leukemia cutis, 2015. e-Pub 2015.
      17. Zhang X, Nooruden S, Huen A, Duvic M, Zhang C. Anti-tumor effects of sapacitabine in cutaneous T-cell lymphoma (CTCL) cells, 2010. e-Pub 2010.
      18. Huen A, DeAngelo D, Fanale M, Vadhan-Raj S. Pharmacokinetic analysis of two dose levels of rasburicase in adult patients with hermatologic malignancies at high or potential risk for tumor lysis syndrome 26(15S), 2008. e-Pub 2008.
      19. Zhou X, Huen A, Teegala S, Ji Y, Fayad LE, Hagemeister FB, Vadhan-Raj S. Incidence and significant predicting factors for chemotherapy-induced severe thrombocytopenia in lymphoma patients 26(15S), 2008. e-Pub 2008.
      20. Teegala SR, Zhou X, Huen A, Ji Y, Fayad LE, Romaguera JE, Vadham-Raf S. Risk Factors for neutropenic fever in lymphoma patients receiving chemotherapy 25(185), 2007. e-Pub 2007.
      21. Zhou X, Teegala S, Huen A, Ji Y, Fayad LE, Romaguera JE, Hagmeister FB, Vadhan-Raj S. Risk factors for severe anemia requiring red blood cell transfusions in lymphoma patients receiving chemotherapy 25(185), 2007. e-Pub 2007.
      22. Thompson MA, Huen A, Toth BB, Vassilopoulou-Sellin R, Hoff, AO, Murphy WA, Sanjorjo H, Bekele BN, Arbuckle RB, Hagemeister FB. Osteopenia and osteoporosis in untreated non-Hodgkin's lymphoma patients: An important and potentially treatable survivorship issue in lymphoma 25(185), 2007. e-Pub 2007.
      23. Huen A, Ippoliti C, Whimbey E, Ghosh S, Augustin K, Champlin R. Cytomegalovirus - Immune Globulin (Cytogam) Prophylaxis for the Prevention of Cytomegalovirus Infection and Disease in CMV Serpositive Allogeneic Blood and Marrow Transplantation Receipients, 2002. e-Pub 2002.
      24. Hicks K, Hachem RY, Huen A, Raad II. Myelosuppression and serotonin syndrome associated with linezolid and selective serotonin re-uptake inhibitors (SSRIs), 2001. e-Pub 2001.
      25. Huen A, Burgess DS, Hastings RW. Comparison of In Vitro Activity of Voriconazole, SCH- 56592, and Fluconazole against Candida albicans by Time-Kill Methodology, 1999. e-Pub 1999.

      Book Chapters

      1. Nguyen CN, Huen AO. Pityriasis Lichenoides Chronica. In: Fitzpatrick’s Therapeutics: A Clinician’s Guide to Dermatologic Treatment. McGraw-Hill Education, 2023.
      2. Huen A. Cutaneous Lymphoma. In: The MD Anderson Manual of Medical Oncology, 4th edition. McGraw Hill Education, 2022.
      3. AOb|| B, Kim EJ. The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma. In: Dermatologic Clinic Cutaneous Lymphoma. First. Elsevier Publishing, 2015.
      4. Romaguera J, Huen A. Lymphoma. In: Cancer Matrix Manual. 4th edition. Advanced Medical Publishing, Inc, 2006.
      5. Huen AO, Gunther J. Cutaneous Lymphomas. In: The MD Anderson Manual of Medical Oncology, 5th edition. McGraw Hill Education.

      Letters to the Editor

      1. Torres Cabala, CA, Yescas, JA, Zhang, Y, Huen, A, Sumit, G, Tefft, K, Tang, G, Curry, JL, Gunther, J, Dabaja, BS, Iyer, S, Miranda, R, Choi, J, Nardi, V. Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma with novel FGFR1 fusion treated with pemigatinib. Blood Advances 9: 1786-1790, 2025.

      Web Publications

      1. Huen AO. Tumor Lysis Syndrome: Review of Pathophysiology And Prevention Strategies. Clinical Oncology News, 2007.
      Read More
      Less

      Patient Reviews


      CV information above last modified September 01, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top